Note: Descriptions are shown in the official language in which they were submitted.
CA 02482598 2010-07-20
WO 03/089456 PCT/US03/12541
PEPTIDE INHIBITORS OF PROTEIN KINASE C
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of co-pending provisional application
60/374,530, filed April 22, 2002, incorporated herein by .reference.
15
FIELD OF THE INVENTION
The present invention relates to peptides effective for the isozyme-specific
modulation of protein kinase C.
BACKGROUND OF THE INVENTION
Protein kinase C ("PKC") is a key enzyme in signal transduction involved in
a variety of cellular functions, including cell growth, regulation of gene
expression,
and ion channel activity. The PKC family of isozymes includes at least 11
different
protein kinases that can be divided into at least three subfamilies based on
their
homology and sensitivity to activators. Each isozyme includes a number of
homologous ("conserved" or "C") domains interspersed with isozyme-unique
("variable" or "V") domains. Members of the "classical" or "cPKC" subfamily,
a, iii,
Rõ and yPKC, contain four homologous domains (Cl, C2, C3 and C4) and require
calcium, phosphatidylserine, and diacylglycerol or phorbol esters for
activation.
Members of the "novel" or "nPKC" subfamily, 6, E, n and APKC, lack the C2
homologous domain and do not require calcium for activation. Finally, members
of
the "atypical" or "cPKC" subfamily, r; and \/IPKC, lack both the C2 and one-
half of
the C1 homologous domains and are insensitive to diacylglycerol, phorbol
esters
and calcium.
-1-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
Studies on the subcellular distribution of PKC isozymes demonstrate that
activation of PKC results in its redistribution in the cells (also termed
translocation),
such that activated PKC isozymes associate with the plasma membrane,
cytoskeletal elements, nuclei, and other subcellular compartments (Saito, N.
et al.,
Proc. Natl. Acad. Sci. USA 86:3409-3413 (1989); Papadopoulos, V. and Hall,
P.F.
J. Cell Biol. 108:553-567 (1989); Mochly-Rosen, D., et al., Molec. Biol. Cell
(formerly Cell Reg.) 1:693-706, (1990)). The unique cellular functions of
different
PKC isozymes are determined by their subcellular location. For example,
activated (31PKC is found inside the nucleus, whereas activated (311PKC is
found at
the perinucleus and cell periphery of cardiac myocytes (Disatnik, M.H., et
al., Exp.
Cell Res. 210:287-297 (1994)). sPKC, a member of the novel PKC family
independent from calcium but requiring phospholipids for activation, is found
in
primary afferent neurons both in the dorsal root ganglia as well as in the
superficial
layers of the dorsal spinal cord.
1s The localization of different PKC isozymes to different areas of the cell
in turn
appears due to binding of the activated isozymes to specific anchoring
molecules
termed Receptors for Activated C-Kinase ("RACKs"). RACKs are thought to
function by selectively anchoring activated PKC isozymes to their respective
subcellular sites. RACKs bind only fully activated PKC and are not necessarily
substrates of the enzyme. Nor is the binding to RACKs mediated via the
catalytic
domain of the kinase (Mochly-Rosen, D., et al., Proc. Natl. Acad. Sci. USA
88:3997-4000 (1991)). Translocation of PKC reflects binding of the activated
enzyme to RACKs anchored to the cell particulate fraction and the binding to
RACKs is required for PKC to produce its cellular responses (Mochly-Rosen, D.,
et
al., Science 268:247-251 (1995)). Inhibition of PKC binding to RACKs in vivo
inhibits PKC translocation and PKC-mediated function (Johnson, J.A., et al.,
J.
Biol. Chem., 271:24962-24966 (1996a); Ron, D., et al., Proc. Natl. Acad. Sci.
USA
92:492-496 (1995); Smith, B.L. and Mochly-Rosen, D., Biochem. Biophys. Res.
Commun., 188:1235-1240 (1992)).
In general, translocation of PKC is required for proper function of PKC
isozymes. Peptides that mimic either the PKC-binding site on RACKs (Mochly-
Rosen, D., et al., J. Biol. Chem., 226:1466-1468 (1991 a); Mochly-Rosen, D.,
et al.,
1995) or the RACK-binding site on PKC (Ron, et al., 1995; Johnson, J.A., et
al.,
-2-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
1996a) are isozyme-specific translocation inhibitors of PKC that selectively
inhibit
the function of the enzyme in vivo.
Individual isozymes of PKC have been implicated in the mechanisms of
various disease states, including the following: cancer (alpha and delta PKC);
cardiac hypertrophy and heart failure (beta I and beta II PKC) nociception
(gamma
and epsilon PKC); ischemia including myocardial infarction (delta PKC); immune
response, particularly T-cell mediated (theta PKC); and fibrablast growth and
memory (zeta PKC). Various PKC isozyme- and variable region-specific peptides
have been previously described (see, for example, U.S. Patent No. 5,783,405).
io The role of sPKC in pain perception has recently been reported (WO
00/01415;
U.S. Patent No. 6,376,467) including therapeutic use of the sV1-2 peptide
(a selective inhibitor of ePKC first described in the above-referenced '405
patent).
The binding specificity for RACKI, a selective anchoring protein for (3uPKC,
has
recently been reported to reside in the V5 region of PIIPKC (Stebbins, E. et
al., J.
Biol. Chem. 271:29644-29650 (2001)), including the testing of certain N-,
middle,
and C-terminus peptides alone, in combination and together with a mixture of
three
peptides from the (3C2 domain.
Notwithstanding such reported advances, new, selective agents and
methods for the treatment of disease, including alternatives to known PKC
isozyme- and variable region-specific peptides have and continue to be
desired.
SUMMARY OF THE INVENTION
The present invention provides PKC V5 isozyme-specific peptides,
pharmaceutical compositions and methods for the treatment diseases modulated
by a PKC isozyme. The peptides are selective modulators of the corresponding
PKC isozymes.
In one aspect the invention pertains to a PKC V5 isozyme-specific peptide.
In another aspect of the invention, the peptide is selected from 6 to 12 of
the N-
terminal 15 amino acids of the V5 domain.
In still another aspect the peptide does not include the N-terminal 2 amino
acids
of the V5 domain.
In yet another aspect, the peptide has 6 to 8 amino acids.
Still another aspect of the invention pertains to an above-described peptide
-3-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
conjugated to a carrier peptide, preferably Cys-Cys bonded to a carrier
peptide
selected from poly-Arg, Tat, or the Drosophila Antennapedia homeodomain.
The invention further provides pharmaceutical formulations including a
pharmaceutically acceptable excipient and an above-described peptide or
peptide/carrier conjugate.
The above-referenced peptides, peptide counjugates and pharmaceutical
formulations include all modifications, derivations, fragments, combinations,
or
hybrids thereof that retain the desired activity. Excluded from the peptides
of the
invention are: SEQ ID NO:5, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13,
SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:31, SEQ ID
NO:37, SEQ ID NO:43, SEQ ID NO:48, SEQ ID NO:57, SEQ ID NO:63 and
SEQ ID NO:64.
Also provided in the present invention is a method of treatment for a disease
state modulated by a PKC isozyme comprising administering a therapeutically
effective amount of an above-described PKC V5 isozyme-specific peptide,
peptide/carrier conjugate (or a modification, derivation, fragment,
combination, or
hybrid thereof that retains the desired activity) or a pharmaceutical
formulation
thereof to a mammal in need of such treatment. In one embodiment, excluded
from
the methods of treatment of the invention are those methods employing a
peptide of
SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:19, SEQ ID
NO:20, or SEQ ID NO:21. In another such embodiment, excluded from the
methods of treatment of the invention are those methods employing a peptide of
SEQ ID NO:5, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID
NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:31, SEQ ID NO:37,
SEQ ID NO:43, SEQ ID NO:48, SEQ ID NO:57, SEQ ID NO:63 or SEQ ID
NO:64.
In another aspect, the invention includes the use of the peptides described
herein to identify compounds that treat disease.
An additional aspect includes the use of a peptides or peptide/carrier
counjgate
in the preparation of a medicament for use in the treatment of disease.
These and other objects and features of the invention will be more fully
appreciated when the following detailed description of the invention is read
in
conjunction with the accompanying drawings.
-4-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
BRIEF DESCRIPTION OF THE SEQUENCES
SEQ ID NO:1 represents the V5 domain of the human aPKC isozyme.
SEQ ID NO:2 is a fragment derived from SEQ ID NO:1.
SEQ ID NO:3 is a modified fragment derived from SEQ ID NO:1.
SEQ ID NO:4 is a modified fragment derived from SEQ ID NO:1.
SEQ ID NO:5 is a fragment derived from SEQ ID NO:1.
SEQ ID NO:6 represents the V5 domain of the human (31PKC isozyme.
SEQ ID NO:7 is a fragment derived from SEQ ID NO:6.
SEQ ID NO:8 is a fragment derived from SEQ ID NO:6.
SEQ ID NO:9 is a modified fragment derived from SEQ ID NO:6.
SEQ ID NO:10 is a modified fragment derived from SEQ ID NO:6.
SEQ ID NO:11 is a fragment derived from SEQ ID NO:6.
SEQ ID NO:12 is a fragment derived from SEQ ID NO:6.
SEQ ID NO:13 is a fragment derived from SEQ ID NO:6.
SEQ ID NO:14 represents the V5 domain of the human (3õPKC isozyme.
SEQ ID NO:15 is a fragment derived from SEQ ID NO:14.
SEQ ID NO:16 is a fragment derived from SEQ ID NO:14.
SEQ ID NO:17 is a fragment derived from SEQ ID NO:14.
SEQ ID NO:18 is a modified fragment derived from SEQ ID NO:14.
SEQ ID NO:19 is a fragment derived from SEQ ID NO:14.
SEQ ID NO:20 is a fragment derived from SEQ ID NO:14.
SEQ ID NO:21 is a fragment derived from SEQ ID NO:14.
SEQ ID NO:22 represents the V5 domain of the human yPKC isozyme.
SEQ ID NO:23 is a fragment derived from SEQ ID NO:22.
SEQ ID NO:24 is a fragment derived from SEQ ID NO:22.
SEQ ID NO:25 is a modified fragment derived from SEQ ID NO:22.
SEQ ID NO:26 represents the V5 domain of the human 5PKC isozyme.
SEQ ID NO:27 is a fragment derived from SEQ ID NO:26.
SEQ ID NO:28 is a fragment derived from SEQ ID NO:26.
SEQ ID NO:29 is a modified fragment derived from SEQ ID NO:26.
-5-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
SEQ ID NO:30 is a modified fragment derived from SEQ ID NO:26.
SEQ ID NO:31 is a fragment derived from SEQ ID NO:26.
SEQ ID NO:32 represents the V5 domain of the human CPKC isozyme.
SEQ ID NO:33 is a fragment derived from SEQ ID NO:32.
SEQ ID NO:34 is a fragment derived from SEQ ID NO:32.
SEQ ID NO:35 is a modified fragment derived from SEQ ID NO:32.
SEQ ID NO:36 is a modified fragment derived from SEQ ID NO:32.
SEQ ID NO:37 is a fragment derived from SEQ ID NO:32.
SEQ ID NO:38 represents the V5 domain of the human i PKC isozyme.
SEQ ID NO:39 is a fragment derived from SEQ ID NO:38.
SEQ ID NO:40 is a fragment derived from SEQ ID NO:38.
SEQ ID NO:41 is a modified fragment derived from SEQ ID NO:38.
SEQ ID NO:42 is a modified fragment derived from SEQ ID NO:38.
SEQ ID NO:43 is a fragment derived from SEQ ID NO:38.
SEQ ID NO:44 represents the V5 domain of the human qPKC isozyme.
SEQ ID NO:45 is a fragment derived from SEQ ID NO:44.
SEQ ID NO:46 is a fragment derived from SEQ ID NO:44.
SEQ ID NO:47 is a modified fragment derived from SEQ ID NO:44.
SEQ ID NO:48 is a fragment derived from SEQ ID NO:44.
SEQ ID NO:49 represents the V5 domain of the human PKC isozyme.
SEQ ID NO:50 is a fragment derived from SEQ ID NO:49.
SEQ ID NO:51 is a fragment derived from SEQ ID NO:49.
SEQ ID NO:52 is a modified fragment derived from SEQ ID NO:49.
SEQ ID NO:53 represents the V5 domain of the human OPKC isozyme.
SEQ ID NO:54 is a fragment derived from SEQ ID NO:53.
SEQ ID NO:55 is a fragment derived from SEQ ID NO:53.
SEQ ID NO:56 is a modified fragment derived from SEQ ID NO:53.
SEQ ID NO:57 is a fragment derived from SEQ ID NO:53.
SEQ ID NO:58 represents the V5 domain of the human i;PKC isozyme.
SEQ ID NO:59 is a fragment derived from SEQ ID NO:58.
SEQ ID NO:60 is a fragment derived from SEQ ID NO:58.
-6-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
SEQ ID NO:61 is a modified fragment derived from SEQ ID NO:58.
SEQ ID NO:62 is a modified fragment derived from SEQ ID NO:58.
SEQ ID NO:63 is a fragment derived from SEQ ID NO:58.
SEQ ID- NO:64 represents a fragment derived from the V5 domain of the
human PKC isozyme.
SEQ ID NO:65 is a Tat-derived carrier peptide (Tat 47-57): Tyr Gly Lys Lys
Arg Arg Gin Arg Arg Arg.
SEQ ID NO:66 is the DrosophilaAntennapedia homeodomain-derived
carrier peptide: Cys Arg Gin lie Lys Ile Trp Phe Gin Asn Arg Arg Met Lys Trp
Lys
Lys.
DETAILED DESCRIPTION OF THE INVENTION
DEFINITIONS
Unless otherwise indicated, all terms herein have the same meaning as they
would to one skilled in the art of the present invention. Practitioners are
particularly
directed to Current Protocols in Molecular Biology (Ausubel, F. M. et al.,
John Wiley
and Sons, Inc., Media Pa.) for definitions and terms of the art.
Abbreviations for amino acid residues are the standard 3-letter and/or 1-
letter
codes used in the art to refer to one of the 20 common L-amino acids.
A "conserved set" of amino acids refers to a contiguous sequence of amino
acids that is identical or closely homologous (e.g., having only conservative
amino
acid substitutions) between members of a group of proteins. A conserved set
may
be anywhere from two to over 50 amino acid residues in length. Typically, a
conserved set is between two and ten contiguous residues in length. For
example,
for the two peptides CGRNAE(SEQ ID NO:15) and ACGRNAE(SEQ ID NO:19),
there are 6 identical positions (CGRNAE) that form the conserved set of amino
acids for these two sequences.
"Conservative amino acid substitutions" are substitutions that do not result
in a significant change in the activity or tertiary structure of a selected
polypeptide
or protein. Such substitutions typically involve replacing a selected amino
acid
residue with a different residue having similar physico-chemical properties.
For
example, substitution of Glu for Asp is considered a conservative substitution
since
both are similarly-sized negatively-charged amino acids. Groupings of amino
-7-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
acids by physico-chemical properties are known to those of skill in the art.
"Domain" and "region" are used interchangeably herein and refer to a
contiguous sequence of amino acids within a PKC isozyme, typically
characterized
by being either conserved or variable.
"Peptide" and "polypeptide" are used interchangeably herein and refer to a
compound made up of a chain of amino acid residues linked by peptide bonds.
Unless otherwise indicated, the sequence for peptides is given in the order
from the
"N" (or amino) termiums to the "C" (or carboxyl) terminus.
Two amino acid sequences or two nucleotide sequences are considered
"homologous" (as this term is preferably used in this specification) if they
have an
alignment score of >5 (in standard deviation units) using the program ALIGN
with
the mutation gap matrix and a gap penalty of 6 or greater (Dayhoff, M. 0., in
ATLAS
OF PROTEIN SEQUENCE AND STRUCTURE (1972) Vol. 5, National Biomedical Research
Foundation, pp. 101-110, and Supplement 2 to this vo)ume, pp. 1-10.) The two
sequences (or parts thereof) are more preferably homologous if their amino
acids
are greater than or equal to 50%, more preferably 70%, still more preferably
80%,
identical when optimally aligned using the ALIGN program mentioned above.
A peptide or peptide fragment is "derived from" a parent peptide or
polypeptide if it has an amino acid sequence that is homologous to the amino
acid
sequence of, or is a conserved fragment from, the parent peptide or
polypeptide.
"Modulate" intends a lessening, an increase, or some other measurable change
in PKC activation.
"Management," for example in the context of treating pain, intends both a
lessening of pain and/or induction of analgesia.
The term "treatment" or "treating" means any treatment of disease in a
mammal, including: (a) preventing or protecting against the disease, that is,
causing the clinical symptoms not to develop; (b) inhibiting the disease, that
is,
arresting or suppressing the development of clinical symptoms; and/or (c)
relieving
the disease, that is, causing the regression of clinical symptoms. It will be
understood by those skilled in the art that in human medicine, it is not
always
possible to distinguish between "preventing" and "suppressing" since the
ultimate
inductive event or events may be unknown, latent, or the patient is not
ascertained
until well after the occurrence of the event or events. Therefore, as used
herein
-8-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
the term "prophylaxis" is intended as an element of "treatment" to encompass
both
"preventing" and "suppressing" as defined herein. The term "protection," as
used
herein, is meant to include "prophylaxis."
The term "effective amount" means a dosage sufficient to provide treatment
for the disorder or disease state being treated. This will vary depending on
the
patient, the disease and the treatment being effected.
The term "pharmaceutically acceptable carrier" or "pharmaceutically
acceptable excipient" includes any and all solvents, dispersion media,
coatings,
antibacterial and antifungal agents, isotonic and absorption delaying agents
and
the like. The use of such media and agents for pharmaceutically active
substances is well known in the art. Except insofar as any conventional media
or
agent is incompatible with the active ingredient, its use in the therapeutic
compositions is contemplated. Supplementary active ingredients can also be
incorporated into the compositions.
PKC PEPTIDES OF THE INVENTION
Prior reports have focused on PKC isozyme- and variable region-specific
peptides from the V1, V3 and V5 domains, but the therapeutic and related
potentials of peptides from the V5 domain remain largely unidentified.
Moreover,
to the extent that peptides from the V5 domain have been described, such
peptides have been predominantly selected from the approximate center of the
V5
domain, starting about 25 amino acids from the N-terminus of the V5 domain.
Generally, the invention contemplates use of a peptide derived from a V5
region of any protein kinase C isozyme for use in treating and/or managing
disease. The present invention pertains to such PKC isozyme-specific V5
peptides, including methods of use and treatment, compositions of matter, and
pharmaceutical formulations thereof. In particular, preferred are peptides
selected
from about 6 to 12 of the N-terminal 15 amino acids of the V5 domain, or a
conservative modification or juxtaposition thereof. Further preferred are
those
peptides that do not include the N-terminal 2 amino acids of the V5 domain,
especially peptides having 6 to 8 amino acids. The peptides can be used in
native
form or modified by conjugation to a carrier, for example via a disulfide bond
between a Cys on the carrier and a Cys within or added to the peptide, such as
-9-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
those described below.
It will be appreciated that peptides homologous to the native sequences and
peptides having conservative amino acid substitutions and/or juxtapositions,
as
well as fragments that retain activity, are within the scope of peptides
contemplated. For example, one or more amino acids (preferably no more than
two) can be substituted, changing between R and K; between V, L, I, R and D;
and/or between G, A, P and N. Thus, the term "a PKC V5 peptide" contemplates
the native sequence and all modifications, derivations, fragments,
combinations,
and hybrids thereof that retain the desired activity.
The following sequences correspond to the V5 domain of various PKC
isozymes and to exemplary fragments derived therefrom. Exemplary modified
peptides are also described below, where the substitution(s) are indicated in
lower
case. In all cases, it is appreciated that sequences derived from and
homologous
to those expressly indicated herein (e.g., closely homologous sequences from
other species) are contemplated. All peptides described herein can be prepared
by
chemical synthesis using either automated or manual solid phase synthetic
technologies, known in the art. The peptides can also be prepared
recombinantly,
using techniques known in the art.
The V5 domain of the aPKC isozyme has the amino acid sequence:
"PKVCG KGAENFDKFF TRGQPVLTPP DQLVIANIDQ SDFEGFSYVN
PQFVHPILQS AV" (SEQ ID NO:1), taken from amino acid residue 616 et
seq. of aPKC. Exemplary peptides include GKGAEN (SEQ ID NO:2),
corresponding to amino acid residues 620-625, and modified peptides
"arGAEN" (SEQ ID NO:3) and cGKGAEN (SEQ ID NO:4). Excluded is the
peptide QLVIAN (SEQ ID NO:5).
The V5 domain of the 1i1PKC isozyme has the amino acid sequence:
"PK ARDKRDTSNF DKEFTRQPVE LTPTDKLFIM NLDQNEFAGF SYTNPEFVIN
V" (SEQ ID NO:6). Exemplary peptides include RDKRDTS (SEQ ID NO:7)
and ARDKRDTSNF DK (SEQ ID NO:8), and modified peptides cARDKRDTS
(SEQ ID NO:9) and gRDKRDTS (SEQ ID NO:10). Excluded are the peptides
ARDKRDTS (SEQ ID NO:11), KLFIMN (SEQ ID N012) and AGFSYTNPEF
VINV (SEQ ID NO:13).
-10-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
The V5 domain of the RlI-PKC isozyme has the amino acid sequence:
"PK ACGRNAENFD RFFTRHPPVL TPPDQEVIRN IDQSEFEGFS FVNSEFLKPE
VKS"(SEQ iD NO:14). Exemplary peptides include CGRNAE (SEQ ID NO:15),
KACGRNAE (SEQ ID NO:16) and CGRNAEN (SEQ ID NO:17) and modified
peptide ACGkNAE (SEQ ID NO:18). Excluded are the peptides ACGRNAE
(SEQ ID NO:19) QEVIRN (SEQ ID NO:20) and SFVNSEFLKP EVKS (SEQ
ID NO:21).
The V5 domain of the yPKC isozyme has the amino acid sequence:
"PRPCGRSG ENFDKFFTRA APALTPPDRL VLASIDQADF QGFTYVNPDF
to VHPDARSPTS PVPVPVM" (SEQ ID NO:22) taken from amino acid residue 633 et
seq. of yPKC. Exemplary are the peptides GRSGEN (SEQ ID NO:23) and
PCGRSGEN (SEQ ID NO:24), and modified peptide GkSGEN (SEQ ID NO:25).
The V5 domain of the BPKC isozyme has the amino acid sequence:
"PKVKSPRDY SNFDQEFLNE KARLSYSDKN LIDSMDQSAF AGFSFVNPKF
is EHLLED" (SEQ ID NO:26). Exemplary peptides include VKSPRDYS (SEQ ID
NO:27) taken from amino acid residues 624-631, PKVKSPRDY SN (SEQ ID
NO:28), and modified peptides VKSPcRDYS (SEQ ID NO:29) and 1KSPReYS
(SEQ ID NO:30). Excluded is the peptide KNLIDS (SEQ ID NO:31).
The V5 domain of the yPKC isozyme has the amino acid sequence:
20 "PRIK TKRDVNNFDQ DFTREEPVLT LVDEAIVKQI NQEEFKGFSY FGEDLMP"
(SEQ ID NO:32), Exemplary peptides include IKTKRDV (SEQ ID NO:33) taken
from amino acid residues 689-695, and TKRDVNNFDQ (SEQ ID NO:34), and
modified peptides cEAIVKQ (SEQ ID NO:35) and IKTKRe (SEQ ID NO:36).
Excluded is the peptide EAIVKQ (SEQ ID NO:37).
25 The V5 domain of the yPKC isozyme has the amino acid sequence:
"PRIKSREDV SNFDPDFIKE EPVLTPIDEG HLPMINQDEF RNFSYVSPEL QP"
(SEQ ID NO:38). Exemplary peptides include IKSREDVS (SEQ ID NO:39)
taken from amino acid residues 634641, and PRIKSREDV (SEQ ID NO:40), and
modified peptides vrSREDVS (SEQ ID NO:41) and EGHdPM (SEQ ID
30 NO:42). Excluded is the peptide EGHLPM (SEQ ID NO:43).
The V5 domain of the tPKC isozyme has the amino acid sequence:
"PNISGEFGL DNFDSQFTNE PVQLTPDDDD IVRKIDQSEF EGFEYINPLL
-11-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
MSAEECV" (SEQ ID NO:44). Exemplary peptides include ISGEFGLD (SEQ ID
NO:45) taken from amino acid resides 534-541 and DDDIVRK (SEQ ID NO:46),
and modified peptide cSGEFGLD (SEQ ID NO:47). Excluded is the peptide
DDIVRK (SEQ ID NO:48).
The V5 domain of the PKC isozyme has the amino acid sequence:
"PQVKLCDFGF ARIUGEKSFR RSVVGTPAYL APEVLRNKGY NRSLDMWSVG
VIIYVSLSGT FPFNEDEDIH DQIQNAAFMY PPNPWKEISH EAIDLINNLL
QVKMRKRYSV DKTLSHPWLQ DYQTWLDLRE LECKIGERYI THESDDLRWE
KYAGEQRLQY PTHLINPSAS HSDTPETEET EMKALGERVS IL" (SEQ ID
NO:49). Exemplary peptides include VKLCDFGF (SEQ ID NO:50) taken from
amino acid resides 723-730, and QVKLCDFGFA (SEQ ID NO:51), and modified
peptide irLCDFaF (SEQ ID NO:52).
The V5 domain of the OPKC isozyme has the amino acid sequence:
"PKVKSPFD CSNFDKEFLN EKPRLSFADR ALINSMDQNM FRNFSFMNPG
MERLIS" (SEQ ID NO:53). Exemplary peptides include VKSPFDCS (SEQ ID
NO:54) taken from amino acid resides 655-662, and DRALINS (SEQ ID NO:55),
and modified peptides VrSPFDCS (SEQ ID NO:56). Excluded is the peptide
RALINS (SEQ ID NO:57).
The V5 domain of the ~PKC isozyme has the amino acid sequence:
"PQIT DDYGLDNFDT QFTSEPVQLT PDDEDAIKRI DQSEFEGFEY INPLLLSTEE
SV" (SEQ ID NO:58). Exemplary peptides include ITDDYGLD (SEQ ID
NO:59) taken from amino acid resides 539-546, and DDYGLDN (SEQ ID
NO:60), and modified peptides ITDDYGde (SEQ ID NO:61) and EDAIR (SEQ
ID NO:62). Excluded is the peptide EDAIKR (SEQ ID NO:63).
Also excluded is the peptide SDSPEA (SEQ ID NO:64), identified as
PKC V5 peptide " V5-1" in U.S. Patent No. 5,783,405.
In all of the exemplary fragments recited above, conservative modifications
and
other modifications that do not appreciably alter the activity can be made and
fall
within the contemplated peptides.
Preferred are the peptides of the group: SEQ ID NO:2, SEQ ID NO:3, SEQ
ID NO:4, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ
ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:23,
-12-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:28, SEQ ID
NO:29, SEQ ID NO:30, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35,
SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID
NO:42, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:50,
SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:55, SEQ ID
NO:56, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61 and SEQ ID NO:62,
optionally including all modifications, derivations, fragments, combinations,
and
hybrids thereof that retain the desired activity.
More preferred are the peptides of the group: SEQ ID NO:2, SEQ ID NO:7,
SEQ ID NO:8, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID
NO:23, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:33,
SEQ ID NO:34, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:45, SEQ ID
NO:46, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:54, SEQ ID NO:55,
SEQ ID NO:59 and SEQ ID NO:60, optionally including all modifications,
derivations, fragments, combinations, and hybrids thereof that retain the
desired
activity.
Still more preferred are the peptides of the group: SEQ ID NO:2, SEQ ID
NO:7, SEQ ID NO:15, SEQ ID NO:23, SEQ ID NO:27, SEQ ID NO:33, SEQ
ID NO:39, SEQ ID NO:45, SEQ ID NO:50, SEQ ID NO:54 and SEQ ID
NO:59, optionally including all modifications, derivations, fragments,
combinations, and hybrids thereof that retain the desired activity.
Similarly preferred are the peptides of the group: SEQ ID NO:2, SEQ ID
NO:23, SEQ ID NO:27, SEQ ID NO:33, SEQ ID NO:39, SEQ ID NO:45,
SEQ ID NO:50, SEQ ID NO:54 and SEQ ID NO:59, optionally including all
modifications, derivations, fragments, combinations, and hybrids thereof that
retain
the desired activity.
UTILITY
Therapeutic Indications
The PKC isozyme-specific V5 peptides of the present invention are useful as
modulators of PKC, being selective for the isozyme from which they are
derived. In
that regard, the peptides can be used in the treatment of mammalian
(especially
-13-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
human) disease states associated with particular PKC isozymes, including: aPKC
(hyperproliferative cellular diseases, such as cancer); R1PKC and P11PKC
(cardiac
hypertrophy and heart failure); yPKC (pain management); 6PKC (protecting
tissue
from damage due to an ischemic or hypoxic event, such as myocardial infarction
and stroke, or apoptosis induced by UV irradiation, and for inhibiting
fibroblast
growth to promote scarless wound healing); cPKC (pain management, myocardial
dysfunction); 6PKC (immune system modulation, particularly involving T-cell
mediated responses); and PKC (memory and stimulating fibroblast growth).
By way of example, pain is a basic clinical symptom seen by physicians and is
often categorized as mild, moderate, or severe. The yPKC and EPKC peptides
described herein are suitable for treatment of pain in any of these
categories. For
example, cancer and post-operative surgical pain are often described as being
in the
moderate-to-severe category. Tumor infiltration of bone, nerve, soft tissue,
or viscera
are common causes of cancer pain. Various factors influence the prevalence of
cancer pain in patients, such as the tumor type, state, and site, as well as
patient
variables. With respect to post-operative pain, the severity of the pain is
often
dependent on location and extent of intervention.
More particularly, the yPKC and PKC peptides are suited to treatment of acute
or chronic pain caused, for example, by neuropathic or inflammatory
conditions.
Exemplary inflammatory conditions contemplated for treatment include, but are
not
limited to, sunburn, osteoarthritis, colitis, carditis, dermatitis, myostis,
neuritis, and
rheumatoid arthritis, lupus and other collagen vascular diseases, as well as
post-
operative surgical pain. Conditions associated with neuropathic pain include,
but are
not limited to, trauma, surgery, amputation, abscess, demyelinating diseases,
trigeminal neuralgia, cancer, chronic alcoholism, stroke, thalamic pain
syndrome,
diabetes, herpes infections, and the like.
Inflammation and nerve damage can induce hyperalgesia, where a noxious
stimulus is perceived as intensely painful due to a lowering of pain
threshold.
Accordingly,in its embodiments addressed to the treatment of pain, the
invention
contemplates a composition and a method for treating hyperalgesia in a
patient.
Additionally, the invention contemplate compositions and methods for treating
allodynia in a subject; that is, treating the pain associated with a normally
non-
noxious stimulus.
-14-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
Use in Methods of Identification
Another aspect the usefulness of the invention is a method of identifying
compounds that modulate pain, for example, by using the peptides described
herein
as research tools for identification of compounds that mimic the activity of
the
peptides. The invention also contemplates use of the peptides in assays to
detect
the site of action of the peptides or in studies on the mechanism of action of
the
peptides. In identifying compounds that mimic the activity of the peptides,
compounds that are able to bind to cellular receptors to which the peptides
bind or
otherwise act in the same of a similar physiological manner as the peptides
can be
identified by several techniques. For example, one method comprises adding a
test
compound to a biological assay that determines the activity of a PKC peptide
of the
invention and detecting the activity of the test compound. Alternatively, test
compounds that modulate the activity of a PKC isozyme can be determined with
an
assay and then tested for a corresponding therapeutic activity.
For example, a competitive binding screening assay can be used to identify
compounds that mimic the activity of a PKC isozyme by adding a test compound
and
a detectably labeled peptide of the invention to mammalian cells, tissue, or
the
suitable RACK under conditions that allow binding of the peptide and comparing
the
results against binding of the labeled peptide (without test compound) to the
cell,
tissue or RACK. Compounds that mimic the activity of the peptide can compete
with
the peptide for binding to the cell, tissue or RACK. Consequently, a smaller
amount
of RACK-bound labeled peptide (or a larger amount of RACK-unbound labeled
peptide) will be measured when the test compound mimics the activity of the
peptide
by binding to the receptor (as compared to the amounts of free and RACK-bound
labeled peptide when a test compound does not mimic the activity of the
peptide,
does not bind to the receptor, or does so with less affinity).
In general, identification of compounds that mimic the activity of PKC
isozymes
are identified by measuring the ability of a test compound to inhibit,
enhance, or
modulate the activity of the corresponding PKC isozyme. The activity of the
PKC
isozyme in a selected assay is measured in the presence and absence of the
test
compound. The assay can be a competitive binding assay (e.g., as described
above) or a cellular assay the monitors modulation of a second messenger
-15-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
production, changes in cellular metabolism, or effects on enzymatic activity.
Compounds identified as mimicking or modulating the activity of the PKC
isozyme
are then tested for therapeutic activity using a corresponding in vivo disease
model.
TESTING
Activity of the peptides of the invention can be determined using any of the
established in vitro and in vivo assays of efficacy in treatment of the above-
mentioned indications. Ultimately, of course, safety and efficacy are
determined in
controlled human clinical studies.
Representative testing protocols are summarized below in the context of
determining activity for the treatment of pain, and for the treatment of
ischemia.
Testing protocols for other PKC V5 peptide indications will be well known to
those
skilled in the art.
V5 Domain Activity as Illustrated by PKC Peptides for Pain Management
The effect of a PKC peptide to modulate nociception is investigated using
models of acute inflammatory pain induced by capsaicin or by formalin. These
models, and others, having long-term increases of sensitivity to noxious
stimuli can
be useful in modeling certain human pathological pain. The capsaicin model of
inflammation, together with a low rate thermal test, mimics central
sensitization
and hyperalgesia resulting from chronic pain. Application of capsaicin to the
skin
produces a robust, hours-long, C fiber selective hyperalgesia indicated by
significant lowering of paw withdrawal latencies during low heating rate
thermal
tests. Capsaicin is the active ingredient in spicy "hot" foods. The receptor
for
capsaicin (VR-1 vanilloid receptor found on C fibers) has been recently
cloned. It
is a ligand-gated, non-selective cation channel. In addition to responding to
capsaicin, VR-1 also responds to thermal stimuli (approximately 43 C) (Kidd
B.L.,
et al., Br. J. Anaesth., 87(1):3-11 (2001)) and to protons, suggesting that
its activity
is enhanced during inflammation. Capsaicin has been shown to selectively
activate and sensitize C fibers, and not A8. Therefore, A5 latency
measurements
are used as controls for animal wellbeing during the studies.
The formalin model in rodents has been validated as a predictive test of
treating injury-induced pain in humans (Dennis, S.G. and Meizack, R. in
Advances
-16-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
in Pain Research and Therapy, Vol. 3, 747, Eds. J.J. Bonica et al., Raven
Press,
New York, 1979; Tjolsen, A., et al., Pain, 51:5-17 (1992)). The model produces
a
bi-phasic response, where the initial phase is triggered by a primary afferent
barrage, similar in character to that described for the acute phasic tests
except that
chemical nociceptors are the mediators. The second phase is considered to be
the hyperalgesic spontaneous activity that results from the initial tissue
damage
and reflects the lowering of nociceptive threshold plus the priming or "wind
up" of
the corresponding spinal circuitry. Thus, both peripheral and central neuronal
circuits and mediators are required to induce and sustain this painful tissue-
injury
condition.
When tested as described above, 7PKC V5 peptides and cPKC V5 peptides
confer a substantial reduction in pain.
V5 Domain Activity as illustrated by PKC Peptides for ischemia
Administration to isolated rat caridac myocytes can be employed to determine
the activity of 6PKC peptides in protection from ischemia. A peptide or
carrier-
peptide conjugate is introduced into isolated adult rat cardiac myocytes ten
minutes prior to prolonged ischemia. Cell damage is assessed using an osmotic
fragility test by measuring uptake of trypan blue.
Administration to whole hearts ex vivo can be employed to determine if the
peptides have activity when introduced extracellulary to a whole organ.
Peptides
optionally conjugated to a carrier peptide, a Tat-derived peptide are
delivered into
Langendorff perfused rat hearts prior to induction of an ischemic period.
After
perfusion with the peptides, global ischemia is effected for 30 minutes. After
the
30 minute ischemic period, the amount of creatine phosphokinase (CPK) released
is monitored during a 30 minute reperfusion period.
Another study determines if the peptides can be delivered to an intact organ
to provide protection after an ischemic insult. In this study, the rat heart
model
described above is used and the hemodynamic parameters are measured during
the 20 minutes of global ischemia and the 20 minutes of reperfusion. Test
peptides are delivered at a concentration of 500 nM, only during the
reperfusion
period.
Protecting tissue from damage due to an ischemic or hypoxic event can be
-17-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
evaluated by administering the peptide in vivo to adult female pigs,
preferably during
the last 10 minutes of a 30 minute ischemic insult. Five days later, the
hearts are
analyzed for tissue damage.
In another study, left ventricurogram is performed in pigs (n=5) at three time
points: (1) before occlusion of left anterior descending artery by balloon
catheter
(pre ischemia); (2) immediately after reperfusion with 2.5 pM/10 mL of 6V1-1
(post
ischemia); and (3) before sacrifice five days later (5 days post ischemia),
using 6
Fr. of pig-tail catheter. LVG is recorded by 2 views, right anterior oblique
and left
anterior oblique. Ejection fraction (EF), the percent of blood ejected in a
beat,
during maximum contraction, of the total maximum present in the left
ventricle, is
analyzed by the software, Plus Plus (Sanders Data Systems), and the averages
of
two views are evaluated. Ejection fractions are calculated based on left
ventricle
dimensions. Ejection fraction is a measure of how well the heart is
functioning,
with a higher ejection fraction indicative of a better functioning heart. An
ejection
fraction of less than 50% in a short period of time can suggest progression
into a
state of heart failure.
Inhibition of damage to the brain as a result of stroke can be examined in a
rat cerebral ischemia model. Ischemia is induced using an intraluminal suture
to
occlude the ostium of the middle cerebral artery. Test peptide, optionally
conjugated to a Tat peptide or the Tat peptide alone are injected into the
carotid
artery before and after a two hour occlusion period. The brain from each
animal is
harvested 24 hours later, stained, and examined.
When tested as described above, SPKC V5 peptides, when delivered before,
during, or after ischemia, confer a substantial reduction of damage to the
heart and
brain induced by ischemia.
ADMINISTRATION
The peptides are prepared for administration by combining with a
pharmaceutically-acceptable carrier or diluent. Thus, a further aspect of the
invention provides pharmaceutical compositions comprising a peptide of the
invention in a dosage form for administration to a subject. Such a dosage form
includes, but is not limited to, tablets, capsules, suspensions, syrups for
oral
administration, where suitable pharmaceutical carriers include starch,
lactose, talc,
-18-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
magnesium stearate, aqueous solutions, oil-water emulsions, and the like.
Other
dosage forms include intrathecal, intravenous, intramuscular, subcutaneous,
where
suitable pharmaceutical carriers include buffered-aqueous or non-aqueous
media.
The peptides can be locally administered (e.g., near a site of inflammation or
peripheral nerve damage) for example, by topical application, intradermal
injection or
drug delivery catheter.
The amount of the peptide in the composition can be varied so that a suitable
dose is obtained and a therapeutic effect is achieved. The dosage will depend
on a
number of factors such as the route of administration, the duration of
treatment, the
size and physical condition of the patient, the potency of the peptide and the
patient's
response. Effective amounts of the peptide can be determined by testing the
peptide
in one or more models known in the art, including those described herein.
The peptides can be administered as needed, hourly, several times per day,
daily, or as often as the person experiencing the pain or that person's
physician
deems appropriate. The peptides can be administered on an on-going basis for
management of chronic indications, or can be administered on a short term
basis
prior to after an acute indications.
The peptides of the invention can be administered alone or linked to a carrier
peptide, such as a Tat carrier peptide (of which the peptide having the
sequence
identified as SEQ ID NO:65 is exemplary). Other suitable carrier peptides are
known and contemplated, such as the Drosophila Antennapedia homeodomain
(SEQ ID NO:66; Theodore, L., et al. J. Neurosci. 15:7158 (1995); Johnson, J.
A.,
et al., Circ. Res. 79:1086 (1996b)), where the PKC peptide is cross-linked via
an
N-terminal Cys-Cys bond to the Antennapedia carrier. Polyarginine is another
exemplary carrier peptide (Mitchell et al., J. Peptide Res., 56:318-325
(2000);
Rolhbard et al., Nature Med., 6:1253-1257 (2000)).
EXAMPLES
The following examples further illustrate the invention described herein and
are
in no way intended to limit the scope of the invention.
-19-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
Example I
Effect of PKC Peptides on Capsaicin-Induced Nociception
Adult male Sprague-Dawley rats weighing between 200-250 g are lightly
anaesthetized with urethane (800 mg.kg, i.p.). The dorsal surface of each
animal is
painted with India ink to ensure heat is applied evenly to the dorsal surface.
Baseline
measurements of all animals (n=10/test group) are taken for 45 minutes for
both C-
fibers (0.9 C/sec heating rate) and A8-fibers (6.5 C/sec heating rate). The
peptides
administered are a positive control sPKC antagonist having the amino acid
sequence EAIVKQ (SEQ ID NO:37) that had previously been identified active
in the assay, the yPKC peptides identified as SEQ ID NO:23, SEQ ID NO:24 and
SEQ ID NO:25 and the EPKC peptides identified as SEQ ID NO:33, SEQ ID
NO:33, SEQ ID NO:34, SEQ ID NO:35 and SEQ ID NO:36. All peptides are linked
to a Tat carrier peptide, of which the sequenced identified as SEQ ID NO:65 is
exemplary. A second series of the peptides is tested without a carrier.
Control
and test peptides are delivered intrathecally via direct lumbar puncture (10 M
peptide in 20 L) 15 minutes prior to topical application of capsaicin on the
left hind
paw (100 L of 3% capsaicin). As negative controls, saline and Tat-carrier
peptide
are also administered to two separate groups of test animals. A latency
measurement is taken post peptide but prior to capsaicin application to
control for
direct peptide effect. Twenty minutes after the application of capsaicin, the
ink is re-
applied, and the dorsal surface of the hind paws is subjected to low rate
heating
for a maximum of 20 seconds. Foot withdrawal latencies are measured at 15
minute intervals. The sPKC and yPKC test peptides result in a decreased pain
score
relative to the negative control pups.
Example 2
Effect of PKC Peptides on Pre-Existing Capsaicin-Induced Nociception
Testing of the yPKC and EPKC peptides for treatment of pre-existing chronic
pain is done as follows. The ability of the peptides to reverse established
capsaicin-
induced thermal hyperalgesia is determined using the procedure described in
Example 1, except the test peptides are administered at various concentrations
of
test peptides (1 M, 50 M, and 100 .tM) over a 10-minute period commencing 25
minutes post capsaicin treatment (i.e., capsaicin is administered after the
baseline
-20-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
measurements). Thermal testing is then done as described in Example 1. Thirty
minutes after capsaicin application, paw withdrawal latency was measured at
regular
intervals for 75 minutes. The SPKC and yPKC test peptides result in a
decreased
pain score relative to the negative control pups.
Example 3
Inhibition of SPKC Translocation
A. Peptide Preparation
5V5 PKC peptides (SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29 and SEQ
ID NO:30) are synthesized and purified. The peptides are modified with a
carrier
peptide by cross-linking via an N-terminal Cys-Cys bond to the Drosophila
Antennapedia homeodomain (Theodore, L., et al.; Johnson, J. A. et al., 1996b)
or
a Tat-derived peptide.
B. Peptide Delivery Into Cells
Primary cardiac myocyte cell cultures (90-95% pure) are prepared from
newborn rats (Gray, M.O. et al.; Disatnik M.-H. et a!.). The peptides are
introduced
into cells at an applied concentration of 500 nM in the presence and absence
of
phorbol 12-myristate 13-acetate (PMA) at concentrations of 3 nm and 10 nm,
respectively, for 10-20 minutes. In a third set of cells, the peptides are
applied at a
concentration of 500 nM in the presence and absence of 500 nM WSRACK.
Translocation of SPKC isozyme is assessed by using SPKC isozyme-specific
antibodies in Western blot analysis (Santa Cruz Biotechnology). Western blot
analysis of cystosolic and particulate fractions of treated cells is carried
out as
described by Johnson et a!., 1995. Subcellular localization of delta PKC
isozymes
is assessed by chemiluminescence of blots probed with anti-SPKC, anti-aPKC and
anti-SPKC antibodies. Amounts of PKC isozymes in each fraction are quantitated
using a scanner and translocation is expressed as the amount of isozymes in
the
particulate fraction over the amount of isozymes in non-treated cells. Changes
in
translocation of SPKC isozyme are also determined by immunofluoresence study
of treated and fixed cells (Gray eta!., 1997). Translocation is determined by
counting over 100 cells/treatment in a blinded fashion.
When tested as described above, the 5V5 PKC peptides are active inhibitors
of delta PKC translocation.
-21-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
Example 4
Peptide Administration to Isolated Cardiac Myocytes
The peptides are prepared as described in Example 3.
Adult male Wistar rat cardiomyocytes are prepared on a Langendorff
apparatus (van der Heide, R.S. et al.) by collagenase treatment (Armstrong, S.
et
a/.). The cells are treated with peptides at concentrations of 10 nM, 100 nM,
500
nM, and I p.M in the presence or absence of I M WBRACK. (3PKC-selective
activator was used as a control.
For stimulated ischemia, adult myocytes treated in microcentrifuge tubes with
6V1-1 and/or y18RACK peptides conjugated to the carrier are washed twice with
degassed glucose-free incubation buffer and pelleted. On top of a minimal
amount
of buffer, the cell pellets are overlaid with either a micro-balloon (Sig
Manufacturing,
Montezuma, IA) or with degassed buffer satured with nitrogen, and sealed with
an
1s airtight top. Tubes are then incubated at 37 C for either 180 minutes or 90
minutes.
Cell damage is assessed by an osmotic fragility test by measuring the uptake
of trypan blue added in a hypotonic (85 mosM) solution. Similar results are
also
obtained by using a live-dead kit (Molecular Probes) or measuring the release
of
lactose dehydrogenase to the medium using a kit (Sigma) as previously
described
(Chen, et aL, 1999; Gray et al., 1997; Mackay et al., 1999).
The 6V5 PKC peptides inhibit ischemic damage when tested as described
above.
Example 5
Ex vivo Peptide Administration to Whole Hearts and Effect on Cell Damage
Adult, male rats are anesthetized with i.p. avertin, and their hearts are
rapidly removed and cannulated via the aorta for perfusion as described in the
art
(Colbert, M. C. et al.) using Langendorff set-up. Care is taken to have the
hearts
perfused within 90 seconds of removal. The hearts are perfused with oxygenated
Krebs-Henseleit solution comprised of, in nmol/L, NaCl 120; KCI 5.8; NaHCO3
25;
NaH2O4 1.2; MgSO4 1.2; CaCl2 1.0; and dextrose 10, pH 7.4 at 37 C.
After a 10-20 minute equilibration period, the hearts are perfused with 5V5
PKC peptides, prepared as described in Example I but conjugated to a Tat-
derived
-22-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
peptise, tor 20 minutes. Perfusion is maintained at a constant flow of 10
mL/min
with Krebs-Hanseleit solution containing 0.5 M of the appropriate peptide.
The
Langendorff method employed uses retrograde flow from the ventricle to the
aorta
and into the coronary arteries, bypassing the pulmonary arteries.
To induce global ischemia, flow is interrupted for 30 minutes. After the
ischemic event, the hearts are re-perfused for 30-60 minutes. During
reperfusion,
ischemia-induced cell damage is determined by measuring the activity of
creatine
phosphokinase (CPK) (absorbance at 520 nm) in the perfusate using a Sigma kit.
As controls, some ex vivo hearts are left untreated, or maintained under
normoxia
conditions, or treated with the Tat-carrier peptide alone, or treated with Tat-
carrier
peptide conjugated to a previously identified inactive peptide.
The 8V5 PKC peptides inhibit ischemic damage when tested as described
above.
is Example 6
In vivo Administration of SVI-1 After Ischemia
Adult female pigs, 35-40kg in weight, are anesthetized and a catheter is
introduced through the carotid artery into the heart. Using conventional
intervention cardiology techniques, a wire is placed through a catheter and
into the
left anterior descending artery. A balloon is run over this wire to a site of
occlusion
where it is then inflated to block blood flow for 30 minutes. During the last
10
minutes of the 30-minute occlusion, either a control comprised of a carrier
peptide
alone or a test peptide (optionally conjugated to a carrier Tat peptide as
described
above) is delivered by slow diffusion (1 mL/min) directly downstream of the
occlusion. Approximately 20pg of test peptide (-400ng per kg body weight) is
administered.
After 30 minutes of occlusion, the balloon is removed and pigs are left to
recover from surgery. Five days later, the pigs are euthanized and hearts are
harvested. After heart removal, the LAD is occluded. With the occlusion in
place,
Evans Blue dye, which stains all areas not at risk of infarct in blue while
leaving all
areas with no access to blood flow red, is infused. Hearts are then cut into
slices
and stained with a tetrazolium red dye which stains all live areas red and
infarcted
dead tissue in white. Each heart has multiple tissue slices with distinctive
areas
-23-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
marking the area at risk for ischemia and the infarcted area. From this, the
percent infarct per area at risk for each slice and for the entire heart is
determined.
The 8V5 PKC peptides inhibit ischemic damage when tested as described
above.
Example 7
In vivo Administration to Rats for Stroke Damage Protection
A. Cerebral ischemia Model
Adult male Sprague-Dawley rats weighing between 280-320 g are used,
Animals are maintained under isofluorane anesthesia during all surgical
procedures. Physiological parameters are monitored and maintained in the
normal
range. Rectal temperature is also measured. At the completion of the
experiment,
the animals are euthanized with a barbiturate overdose and prepared for
histological analysis.
is B. Focal model
Ischemia is induced using an occluding intraluminal suture. An uncoated 30
mm long segment of 3-0 nylon monofilament suture with the tip rounded by flame
is inserted into the stump of the common carotid artery and advanced into the
internal carotid artery approximately 19-20 mm from the bifurcation in order
to
occlude the ostium of the middle cerebral artery. Sham control animals undergo
similar anesthesia and surgical manipulation, but do not experience ischemia.
At
the end of a 2 hour ischemic period, the suture is removed and the animal
allowed
to recover. Brains are harvested after 24 hrs of reperfusion.
C. Peptide delivery
Test peptide optionally conjugated to Tat peptide, or Tat carrier control
peptide (50pL of 10pM solution in saline) are injected into the carotid artery
either
immediately before or before and after the 2 hours occlusion. The final blood
concentration of test peptide is 1 M.
D. Histology
Animals are perfused with heparinized saline and brains removed and
sectioned into 2 mm thick slices. To assess ischemic injury, brain sections
are
stained with cresyl violet or with triphenyl tetrazolium chloride, a live
tissue stain to
indicate the regions of infarct. Areas of infarction (white) are then measured
using
-24-
CA 02482598 2004-10-14
WO 03/089456 PCT/US03/12541
an image analysis system previously described (Yenari, M.A. et al., 1998;
Maier,
C. et al., 1998).
The 5V5 PKC peptides inhibit ischemic damage when tested as described
above.
REMAINDER OF PAGE INTENTIONALLY LEFT BLANK
-25-
CA 02482598 2010-07-20
WO 03/089456 PCT/US03/12541
vvnne the present invention has been described with reference to the specific
embodiments thereof, it should be understood by those skilled in the art that
various changes may be made and equivalents may be substituted without
departing from the true spirit and scope of the invention. In addition, many
modifications may be made to adapt a particular situation, material,
composition of
matter, process, process step or steps, to the objective, spirit and scope of
the
present invention. All such modifications are intended to be within the scope
of the
claims appended hereto.
-26-
CA 02482598 2004-10-14
SEQUENCE LISTING
<110> The Board of Trustees of the Leland Stanford Junior University
<120> Peptide inhibitors of protein kinase C
<130> O8901452CA
<140>
<141> 2003-04-22
<150> US 60/374,530
<151> 2002-04-22
<160> 66
<170> Patentln version 3.1
<210> 1
<211> 57
<212> PRT
<213> Artificial
<220>
<223> V5 domain of the human alphaPKC isozyme
<400> 1
Pro Lys Val Cys Gly Lys Gly Ala Glu Asn Phe Asp Lys Phe Phe Thr
1 5 10 15
Arg Gly Gln Pro Val Leu Thr Pro Pro Asp Gln Leu Val Ile Ala Asn
20 25 30
Ile Asp Gln Ser Asp Phe Glu Gly Phe Ser Tyr Val Asn Pro Gln Phe
35 40 45
Val His Pro Ile Leu Gln Ser Ala Val
50 55
<210> 2
<211> 6
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:1
<400> 2
Gly Lys Gly Ala Glu Asn
1 5
26/1
CA 02482598 2004-10-14
<210> 3
<211> 6
<212> PRT
<213> Artificial
<220>
<223> modified fragment derived from SEQ ID NO:1
<400> 3
Ala Arg Gly Ala Glu Asn
1 5
<210> 4
<211> 7
<212> PRT
<213> Artificial
<220>
<223> modified fragment derived from SEQ ID NO:1
<400> 4
Cys Gly Lys Gly Ala Glu Asn
1 5
<210> 5
<211> 6
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:1
<400> 5
Gln Leu Val Ile Ala Asn
1 5
<210> 6
<211> 53
<212> PRT
<213> Artificial
<220>
<223> V5 domain of the human betalPKC isozyme
<400> 6
26/2
CA 02482598 2004-10-14
Pro Lys Ala Arg Asp Lys Arg Asp Thr Ser Asn Phe Asp Lys Glu Phe
1 5 10 15
Thr Arg Gln Pro Val Glu Leu Thr Pro Thr Asp Lys Leu Phe Ile Met
20 25 30
Asn Leu Asp Gln Asn Glu Phe Ala Gly Phe Ser Tyr Thr Asn Pro Glu
35 40 45
Phe Val Ile Asn Val
<210> 7
<211> 7
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:6
<400> 7
Arg Asp Lys Arg Asp Thr Ser
1 5
<210> 8
<211> 12
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:6
<400> 8
Ala Arg Asp Lys Arg Asp Thr Ser Asn Phe Asp Lys
1 5 10
<210> 9
<211> 9
<212> PRT
<213> Artificial
<220>
<223> modified fragment derived from SEQ ID NO:6
<400> 9
Cys Ala Arg Asp Lys Arg Asp Thr Ser
1 5
26/3
CA 02482598 2004-10-14
<210> 10
<211> 8
<212> PRT
<213> Artificial
<220>
<223> modified fragment derived from SEQ ID NO:6
<400> 10
Gly Arg Asp Lys Arg Asp Thr Ser
1 5
<210> 11
<211> 8
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:6
<400> 11
Ala Arg Asp Lys Arg Asp Thr Ser
1 5
<210> 12
<211> 6
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:6
<400> 12
Lys Leu Phe Ile Met Asn
1 5
<210> 13
<211> 14
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:6
<400> 13
Ala Gly Phe Ser Tyr Thr Asn Pro Glu Phe Val Ile Asn Val
1 5 10
<210> 14
<211> 55
<212> PRT
<213> Artificial
26/4
CA 02482598 2004-10-14
<220>
<223> V5 domain of the human beta2PKC isozyme
<400> 14
Pro Lys Ala Cys Gly Arg Asn Ala Glu Asn Phe Asp Arg Phe Phe Thr
1 5 10 15
Arg His Pro Pro Val Leu Thr Pro Pro Asp Gln Glu Val Ile Arg Asn
20 25 30
Ile Asp Gln Ser Glu Phe Glu Gly Phe Ser Phe Val Asn Ser Glu Phe
35 40 45
Leu Lys Pro Glu Val Lys Ser
50 55
<210> 15
<211> 6
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:14
<400> 15
Cys Gly Arg Asn Ala Glu
1 5
<210> 16
<211> 8
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:14
<400> 16
Lys Ala Cys Gly Arg Asn Ala Glu
1 5
<210> 17
<211> 7
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:14
26/5
CA 02482598 2004-10-14
<400> 17
Cys Gly Arg Asn Ala Glu Asn
1 5
<210> 18
<211> 7
<212> PRT
<213> Artificial
<220>
<223> modified fragment derived from SEQ ID NO:14
<400> 18
Ala Cys Gly Lys Asn Ala Glu
1 5
<210> 19
<211> 7
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:14
<400> 19
Ala Cys Gly Arg Asn Ala Glu
1 5
<210> 20
<211> 6
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:14
<400> 20
Gln Glu Val Ile Arg Asn
1 5
<210> 21
<211> 14
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:14
<400> 21
26/6
CA 02482598 2004-10-14
Ser Phe Val Asn Ser Glu Phe Leu Lys Pro Glu Val Lys Ser
1 5 10
<210> 22
<211> 65
<212> PRT
<213> Artificial
<220>
<223> V5 domain of the human gammaPKC isozyme
<400> 22
Pro Arg Pro Cys Gly Arg Ser Gly Glu Asn Phe Asp Lys Phe Phe Thr
1 5 10 15
Arg Ala Ala Pro Ala Leu Thr Pro Pro Asp Arg Leu Val Leu Ala Ser
20 25 30
Ile Asp Gln Ala Asp Phe Gln Gly Phe Thr Tyr Val Asn Pro Asp Phe
35 40 45
Val His Pro Asp Ala Arg Ser Pro Thr Ser Pro Val Pro Val Pro Val
50 55 60
Met
<210> 23
<211> 6
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:22
<400> 23
Gly Arg Ser Gly Glu Asn
1 5
<210> 24
<211> 8
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:22
<400> 24
26/7
CA 02482598 2004-10-14
Pro Cys Gly Arg Ser Gly Glu Asn
1 5
<210> 25
<211> 6
<212> PRT
<213> Artificial
<220>
<223> modified fragment derived from SEQ ID NO:22
<400> 25
Gly Lys Ser Gly Glu Asn
1 5
<210> 26
<211> 55
<212> PRT
<213> Artificial
<220>
<223> V5 domain of the human deltaPKC isozyme
<400> 26
Pro Lys Val Lys Ser Pro Arg Asp Tyr Ser Asn Phe Asp Gln Glu Phe
1 5 10 15
Leu Asn Glu Lys Ala Arg Leu Ser Tyr Ser Asp Lys Asn Leu Ile Asp
20 25 30
Ser Met Asp Gln Ser Ala Phe Ala Gly Phe Ser Phe Val Asn Pro Lys
35 40 45
Phe Glu His Leu Leu Glu Asp
50 55
<210> 27
<211> 8
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:26
<400> 27
Val Lys Ser Pro Arg Asp Tyr Ser
1 5
26/8
CA 02482598 2004-10-14
<210> 28
<211> 11
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:26
<400> 28
Pro Lys Val Lys Ser Pro Arg Asp Tyr Ser Asn
1 5 10
<210> 29
<211> 9
<212> PRT
<213> Artificial
<220>
<223> modified fragment derived from SEQ ID NO:26
<400> 29
Val Lys Ser Pro Cys Arg Asp Tyr Ser
1 5
<210> 30
<211> 8
<212> PRT
<213> Artificial
<220>
<223> modified fragment derived from SEQ ID NO:26
<400> 30
Ile Lys Ser Pro Arg Leu Tyr Ser
1 5
<210> 31
<211> 6
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:26
<400> 31
Lys Asn Leu Ile Asp Ser
1 5
<210> 32
<211> 51
26/9
CA 02482598 2004-10-14
<212> PRT
<213> Artificial
<220>
<223> V5 domain of the human epsilonPKC isozyme
<400> 32
Pro Arg Ile Lys Thr Lys Arg Asp Val Asn Asn Phe Asp Gln Asp Phe
1 5 10 15
Thr Arg Glu Glu Pro Val Leu Thr Leu Val Asp Glu Ala Ile Val Lys
20 25 30
Gln Ile Asn Gln Glu Glu Phe Lys Gly Phe Ser Tyr Phe Gly Glu Asp
35 40 45
Leu Met Pro
<210> 33
<211> 7
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:32
<400> 33
Ile Lys Thr Lys Arg Asp Val
1 5
<210> 34
<211> 10
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:32
<400> 34
Thr Lys Arg Asp Val Asn Asn Phe Asp Gln
1 5 10
<210> 35
<211> 7
<212> PRT
<213> Artificial
<220>
26/10
CA 02482598 2004-10-14
<223> modified fragment derived from SEQ ID NO:32
<400> 35
Cys Glu Ala Ile Val Lys Gln
1 5
<210> 36
<211> 7
<212> PRT
<213> Artificial
<220>
<223> modified fragment derived from SEQ ID NO:32
<400> 36
.Ile Lys Thr Lys Arg Leu Ile
1 5
<210> 37
<211> 6
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:32
<400> 37
Glu Ala Ile Val Lys Gln
1 5
<210> 38
<211> 51
<212> PRT
<213> Artificial
<220>
<223> V5 domain of the human etaPKC isozyme
<400> 38
Pro Arg Ile Lys Ser Arg Glu Asp Val Ser Asn Phe Asp Pro Asp Phe
1 5 10 15
Ile Lys Glu Glu Pro Val Leu Thr Pro Ile Asp Glu Gly His Leu Pro
20 25 30
Met Ile Asn Gin Asp Glu Phe Arg Asn Phe Ser Tyr Val Ser Pro Glu
35 40 45
26/11
CA 02482598 2004-10-14
Leu Gln Pro
<210> 39
<211> 8
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:38
<400> 39
Ile Lys Ser Arg Glu Asp Val Ser
1 5
<210> 40
<211> 9
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:38
<400> 40
Pro Arg Ile Lys Ser Arg Glu Asp Val
1 5
<210> 41
<211> 8
<212> PRT
<213> Artificial
<220>
<223> modified fragment derived from SEQ ID NO:38
<400> 41
Val Arg Ser Arg Glu Asp Val Ser
1 5
<210> 42
<211> 6
<212> PRT
<213> Artificial
<220>
<223> modified fragment derived from SEQ ID NO:38
<400> 42
Glu Gly His Asp Pro Met
1 5
26/12
CA 02482598 2004-10-14
<210> 43
<211> 6
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:38
<400> 43
Glu Gly His Leu Pro Met
1 5
<210> 44
<211> 56
<212> PRT
<213> Artificial
<220>
<223> V5 domain of the human iotaPKC isozyme
<400> 44
Pro Asn Ile Ser Gly Glu Phe Gly Leu Asp Asn Phe Asp Ser Gln Phe
1 5 10 15
Thr Asn Glu Pro Val Gin Leu Thr Pro Asp Asp Asp Asp Ile Val Arg
20 25 30
Lys Ile Asp Gln Ser Glu Phe Glu Gly Phe Glu Tyr Ile Asn Pro Leu
35 40 45
Leu Met Ser Ala Glu G1u Cys Val
50 55
<210> 45
<211> 8
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:44
<400> 45
Ile Ser Gly Glu Phe Gly Leu Asp
1 5
<210> 46
<211> 7
26/13
CA 02482598 2004-10-14
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:44
<400> 46
Asp Asp Asp Ile Val Arg Lys
1 5
<210> 47
<211> 8
<212> PRT
<213> Artificial
<220>
<223> modified fragment derived from SEQ ID NO:44
<400> 47
Cys Ser Gly Glu Phe Gly Leu Asp
1 5
<210> 48
<211> 6
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:44
<400> 48
Asp Asp Ile Val Arg Lys
1 5
<210> 49
<211> 192
<212> PRT
<213> Artificial
<220>
<223> VS domain of the human muPKC isozyme
<400> 49
Pro Gln Val Lys Leu Cys Asp Phe Gly Phe Ala Arg Ile Ile Gly Glu
1 5 10 15
Lys Ser Phe Arg Arg Ser Val Val Gly Thr Pro Ala Tyr Leu Ala Pro
20 25 30
26/14
CA 02482598 2004-10-14
Glu Val Leu Arg Asn Lys Gly Tyr Asn Arg Ser Leu Asp Met Trp Ser
35 40 45
Val Gly Val Ile Ile Tyr Val Ser Leu Ser Gly Thr Phe Pro Phe Asn
50 55 60
Glu Asp Glu Asp Ile His Asp Gln Ile Gln Asn Ala Ala Phe Met Tyr
65 70 75 80
Pro Pro Asn Pro Trp Lys Glu Ile Ser His Glu Ala Ile Asp Leu Ile
85 90 95
Asn Asn Leu Leu Gln Val Lys Met Arg Lys Arg Tyr Ser Val Asp Lys
100 105 110
Thr Leu Ser His Pro Trp Leu Gln Asp Tyr Gln Thr Trp Leu Asp Leu
115 120 125
Arg Glu Leu Glu Cys Lys Ile Gly Glu Arg Tyr Ile Thr His Glu Ser
130 135 140
Asp Asp Leu Arg Trp Glu Lys Tyr Ala Gly Glu Gln Arg Leu Gln Tyr
145 150 155 160
Pro Thr His Leu Ile Asn Pro Ser Ala Ser His Ser Asp Thr Pro Glu
165 170 175
Thr Glu Glu Thr Glu Met Lys Ala Leu Gly Glu Arg Val Ser Ile Leu
180 185 190
<210> 50
<211> 8
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:49
<400> 50
Val Lys Leu Cys Asp Phe Gly Phe
1 5
<210> 51
<211> 10
<212> PRT
<213> Artificial
26/15
CA 02482598 2004-10-14
<220>
<223> fragment derived from SEQ ID NO:49
<400> 51
Gln Val Lys Leu Cys Asp Phe Gly Phe Ala
1 5 10
<210> 52
<211> 8
<212> PRT
<213> Artificial
<220>
<223> modified fragment derived from SEQ ID NO:49
<400> 52
Ile Arg Leu Cys Asp Phe Ala Phe
1 5
<210> 53
<211> 54
<212> PRT
<213> Artificial
<220>
<223> V5 domain of the human thetaPKC isozyme
<400> 53
Pro Lys Val Lys Ser Pro Phe Asp Cys Ser Asn Phe Asp Lys Glu Phe
1 5 10 15
Leu Asn Glu Lys Pro Arg Leu Ser Phe Ala Asp Arg Ala Leu Ile Asn
20 25 30
Ser Met Asp Gln Asn Met Phe Arg Asn Phe Ser Phe Met Asn Pro Gly
35 40 45
Met Glu Arg Leu Ile Ser
<210> 54
<211> 8
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:53
26/16
CA 02482598 2004-10-14
<400> 54
Val Lys Ser Pro Phe Asp Cys Ser
1 5
<210> 55
<211> 7
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:53
<400> 55
Asp Arg Ala Leu Ile Asn Ser
1 5
<210> 56
<211> 8
<212> PRT
<213> Artificial
<220>
<223> modified fragment derived from SEQ ID NO:53
<400> 56
Val Arg Ser Pro Phe Asp Cys Ser
1 5
<210> 57
<211> 6
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:53
<400> 57
Arg Ala Leu Ile Asn Ser
1 5
<210> 58
<211> 56
<212> PRT
<213> Artificial
<220>
<223> V5 domain of the human xiPKC isozyme
<400> 58
26/17
CA 02482598 2004-10-14
Pro Gln Ile Thr Asp Asp Tyr Gly Leu Asp Asn Phe Asp Thr Gln Phe
1 5 10 15
Thr Ser Glu Pro Val Gln Leu Thr Pro Asp Asp Glu Asp Ala Ile Lys
20 25 30
Arg Ile Asp Gin Ser Glu Phe Glu Gly Phe Glu Tyr Ile Asn Pro Leu
35 40 45
Leu Leu Ser Thr Glu Glu Ser Val
50 55
<210> 59
<211> 8
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:58
<400> 59
Ile Thr Asp Asp Tyr Gly Leu Asp
1 5
<210> 60
<211> 7
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:58
<400> 60
Asp Asp Tyr Gly Leu Asp Asn
1 5
<210> 61
<211> 8
<212> PRT
<213> Artificial
<220>
<223> modified fragment derived from SEQ ID NO:58
<400> 61
Ile Thr Asp Asp Tyr Gly Asp Leu
1 5
26/18
CA 02482598 2004-10-14
<210> 62
<211> 5
<212> PRT
<213> Artificial
<220>
<223> modified fragment derived from SEQ ID NO:58
<400> 62
Glu Asp Ala Ile Arg
1 5
<210> 63
<211> 6
<212> PRT
<213> Artificial
<220>
<223> fragment derived from SEQ ID NO:58
<400> 63
Glu Asp Ala Ile Lys Arg
1 5
<210> 64
<211> 6
<212> PRT
<213> Artificial
<220>
<223> fragment derived from the V5 domain of the human muPKC isozyme
<400> 64
Ser Asp Ser Pro Glu Ala
1 5
<210> 65
<211> 10
<212> PRT
<213> Artificial
<220>
<223> Tat-derived carrier peptide (Tat 47-57)
<400> 65
Tyr Gly Lys Lys Arg Arg Gln Arg Arg Arg
1 5 10
<210> 66
<211> 17
26/19
CA 02482598 2004-10-14
<212> PRT
<213> Artificial
<220>
<223> Drosophila Antennapedia homeodomain-derived carrier peptide
<400> 66
Cys Arg Gin Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys
1 5 10 15
Lys
26/20
